in

CytoSorbents, Progenity Receive Funding For Product Development

The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract of $1.5 million over 28 months.

  • The funding will be used to advance the development of the K+ontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.
  • Price Action: CTSO shares are up 0.63% at $7.96 during the market trading session on the last check Tuesday.

Progenity Inc (NASDAQ: PROG) has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to further develop its oral Drug Delivery System to deliver targeted therapeutics for inflammatory bowel disease.

  • Progenity’s lead candidates include PGN-001, a high-concentration formulation of adalimumab, and PGN-600, a high concentration, solubilized formulation of tofacitinib.
  • Price Action: PROG shares are trading 5.7% higher at $2.49 during the market trading session on the last check Tuesday.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source: CytoSorbents, Progenity Receive Funding For Product Development

What do you think?

Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn Partners

Palantir To Accept Bitcoin As Payment Option: What You Need To Know